US court backs Myriad to patent genes linked to cancer

Click the thumbnails below to view our monthly newsletters.

lsipr-newsletter-may-2013-thumbnail.jpg

May 2013

Highlights:

  • BerGenBio's new approach to cancer target screening
  • Supreme Court to hear Medtronic case
  • Monsanto: Supreme Court rejects 'blame-the-bean' defence
  • Self-collision of European patent filings
lsipr-april-thumbnail.jpg

April 2013

Highlights:

  • Novo Nordisk’s IP strategy
  • OFT accuses GSK market abuse over pay-for-delay deals
  • Actavis eyes $100 million after settlement
  • Obviousness of DNA fragments in the post-Kubin era
lsipr-newsletter-march-2013.jpg

March 2013

Highlights:

  • India rejects Bayer plea over compulsory licence
  • AstraZeneca settles Crestor patent dispute
  • Twenty-one years of SPCs–a cause for celebration?
  • Confidence in the face of counterfeits
lsipr-feb-13-cover.jpg

February 2013

Highlights:

  • Australian court backs Myriad in gene patent dispute
  • B-MS loses Baraclude patent fight with Teva
  • Hub and spoke? Life sciences in Northern France
  • UK patent change paves way for pharma innovation

Myriad, BRCA, ACLU, Mayo v Prometheus, gene patents, US Court of Appeals

More on this story

ACLU files Supreme Court brief in Myriad case
29-01-2013

WIPR